Impact on Mortality of Hospitalisation of a Patient in a Hospital Bed That Does Not Correspond to His Needs After a Visit to the Emergency Department (RIGHT BED)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: François Saget, Md
- Phone Number: +33299284321
- Email: francois.saget@chu-rennes.fr
Study Locations
-
-
-
Angers, France
- CHU Angers
-
Principal Investigator:
- Delphine Douillet
-
Contact:
- Delphine DOUILLET
- Phone Number: +33241353637
- Email: delphine.douillet@chu-angers.fr
-
Le Mans, France
- CH Le Mans
-
Contact:
- Lionel Imsaad
- Phone Number: +332 43 43 43 43
- Email: limsaad@ch-lemans.fr
-
Principal Investigator:
- Lionel Imsaad
-
Nantes, France
- CHU Nantes
-
Principal Investigator:
- Emmanuel Montassier
-
Contact:
- Emmanuel Montassier
- Phone Number: +332 40 08 33 33
- Email: Emmanuel.MONTASSIER@chu-nantes.fr
-
Poitiers, France
- CHU Poitiers
-
Principal Investigator:
- Nicolas MARJANOVIC
-
Contact:
- Nicolas Marjanovic
- Phone Number: +330549444444
- Email: nicolas.marjanovic@chu-poitiers.fr
-
Strasbourg, France
- CHU Strasbourg
-
Contact:
- Pierrick Le Borgne
- Phone Number: +333 88 11 67 68
- Email: pierrick_med@yahoo.fr
-
Principal Investigator:
- Pierrick Le Borgne
-
Toulouse, France
- CHU Toulouse
-
Contact:
- Margaux Piechowiak
- Phone Number: +335 61 77 22 33
- Email: Piechowiak.m@chu-toulouse.fr
-
Principal Investigator:
- Margaux Piechowiak
-
Tours, France
- CHU Tours
-
Contact:
- Geoffroy Rousseau
- Phone Number: +332.47.47.47.47
- Email: geoffroy.rousseau@chu-tours.fr
-
Principal Investigator:
- Geoffroy Rousseau
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Presenting at an emergency department participating in the study,
- Requiring hospitalisation
Exclusion Criteria:
- Patients hospitalised in short-stay units with secondary outpatient care,
- Adults subject to legal protection (legal guardianship, curatorship, trusteeship), persons deprived of their liberty.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Death rate
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of hospitalization
Time Frame: 30 days
|
30 days
|
|
|
length of stay in the emergency department
Time Frame: 30 days
|
30 days
|
|
|
Rate of Adverse events
Time Frame: 30 days
|
Adverse events occuring during hospitalization
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: François Saget, francois.saget@chu-rennes.fr
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 35RC25_30013
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.